Evonik, Charts

Evonik Charts Solo Course After BASF Walks Away, With 3,200 Job Cuts as the Yardstick

Published on 11/20/2026 at 08:11 | Editorial boerse-global.de
BASF dropped its takeover pursuit after Evonik rejected two offers, leaving the chemicals maker to prove its restructuring case alone.
Evonik, Charts, Solo, Course, After, BASF, Walks, Away, With, Job Illustration mit AI erstellt.

Evonik's shareholders have a new question to answer: what is the chemicals maker worth without a buyer? BASF's decision to abandon its takeover pursuit has stripped out the bid premium that had propped up the stock, leaving the market to price the company on its own restructuring story once again.

Interim chief executive Claus Rettig used the moment to reaffirm that Evonik can push ahead with its standalone development "with full force," according to Reuters. He offered no fresh strategy in place of the failed deal — just a restatement of the existing plan. For investors, that shifts the focus squarely onto execution.

A bid that never became a floor

BASF pulled the plug after Evonik turned down two non-binding all-cash offers. The final proposal stood at €24 per Evonik share, valuing the equity at roughly €11.2 billion. BASF had signalled room for one more moderate increase but ultimately concluded that a higher price was not in its shareholders' interest, given Evonik's standalone business prospects and the risks attached to them.

Jefferies analyst Priyanka Patel pointed to BASF's account that Evonik's management board had not engaged constructively with the approach, despite the prospect of an improved offer. The brokerage kept its hold rating on the stock and a €21 price target, while flagging downside risk following BASF's exit.

Should investors sell immediately? Or is it worth buying Evonik?

The shares closed yesterday at €18.30, well below the last price BASF was willing to pay. A second reading put the stock at €18.28. Either way, the €24 bid is no longer a sale price anyone can reach — and the gap to it does not make Evonik cheap on its own. Analysts cited in media reports are urging caution, pointing back to operating performance as the real basis for valuation.

Headcount reduction as the measuring stick

How far the self-help effort reaches is best seen in the payroll plan. Evonik intends to cut 3,200 positions by the end of 2029, including 2,150 in Germany, according to dpa. That number now serves as the most concrete gauge of whether the company delivers on its independent course.

Rettig also wants to grow Evonik's value without a partner and to play a role in industry consolidation himself, the Frankfurter Allgemeine Zeitung reported. BASF's withdrawal, in other words, does not mean Evonik intends to sit out the sector's reshaping.

The political backdrop reinforces the standalone path. Hendrik Wüst, premier of North Rhine-Westphalia — the state where Evonik is a major employer — came out against a takeover, citing the company's importance to the region. His opposition does nothing to alter Evonik's own restructuring blueprint.

Evonik at a turning point? This analysis reveals what investors need to know now.

Ownership overhang and the next catalyst

The RAG-Stiftung holds roughly 43% of Evonik, according to Reuters, and aims to reduce that stake to 25.1% over time — a structural consideration that stays relevant for investors regardless of the takeover outcome. For the foundation and other shareholders alike, the standalone case now hinges on how the operating business performs during the planned overhaul.

The next hard data point arrives on 04.03., when Evonik is due to publish its fourth-quarter 2026 results, Reuters reported. Until then, the market has little to go on but the job-cut target and management's assurances.

Ad

Evonik Stock: New Analysis - 20 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIK | boerse | 70538959 |